Adding 1000 mg/day CBD to standard antipsychotic treatment significantly reduced positive psychotic symptoms in schizophrenia patients, with a side effect profile indistinguishable from placebo.
Psychiatrists, patients with schizophrenia, anyone interested in CBD's therapeutic potential or the cannabis-psychosis paradox.
3.65xPatients on CBD were 3.65 times more likely to be rated as clinically improved than those on placebo
The Backstory
Six years after Leweke showed CBD could match a standard antipsychotic in 42 patients, the obvious question was: can it be replicated at scale, with a more rigorous design, across multiple sites?
Philip McGuire — the King's College London psychiatrist whose team had spent a decade documenting THC's and CBD's opposite effects on the brain — took on the challenge. The result was the largest and most rigorous randomized controlled trial of CBD for psychosis ever conducted. Published in the American Journal of Psychiatry, it didn't just replicate Leweke's finding. It advanced the case for CBD as a fundamentally new kind of antipsychotic.
The Trial
Eighty-eight patients with schizophrenia across three countries (United Kingdom, Poland, Romania) were randomized to receive either 1000 mg/day of pharmaceutical-grade CBD or placebo for six weeks. Crucially, this was an adjunctive trial — all patients continued their existing antipsychotic medication. CBD was added on top, not substituted.
This design choice was strategically important. Leweke's 2012 trial tested CBD as a standalone treatment versus amisulpride — bold but risky. McGuire asked a safer, more clinically relevant question: does adding CBD to standard treatment make patients better than standard treatment alone? If yes, the path to clinical adoption is much shorter — you don't need to replace anyone's medication, just supplement it.
CBD + Antipsychotic vs Placebo + Antipsychotic
Six Weeks of Adjunctive Treatment for Schizophrenia
-3.2
CBD group PANSS positive improvement
mean improvement in positive symptoms score (SD 2.60)
-1.7
Placebo group PANSS positive improvement
mean improvement in positive symptoms score (SD 2.76)
1.4
Treatment difference
favoring CBD (95% CI: -2.5, -0.2; p=0.019)
3.65
CGI-I odds ratio
patients on CBD 3.65x more likely to be rated 'improved' (95% CI: 1.38-9.69; p=0.017)
McGuire et al. (2018), Am J Psychiatry 175(3):225-231
The primary outcome — PANSS positive symptoms (hallucinations, delusions, disorganized thinking) — improved significantly more in the CBD group. The treatment difference of 1.4 points may sound small, but in a population already receiving antipsychotic medication, any additional improvement is clinically meaningful. The CGI-I (Clinical Global Impression - Improvement) told the story more intuitively: patients on CBD were 3.65 times more likely to be rated as "improved" by their treating clinician.
Secondary outcomes trended favorably but didn't reach statistical significance: cognitive performance measured by the Brief Assessment of Cognition in Schizophrenia (BACS, treatment difference: 1.31, 95% CI: -0.10, 2.72) and global functioning on the GAF (treatment difference: 3.0, 95% CI: -0.4, 6.4). Both trends in the right direction, both suggestive, neither definitive with this sample size.
The Side Effect Story
CBD Group (n=43)
- Adverse event rate
- Similar to placebopositive
- Weight gain
- None attributable to CBDpositive
- Sedation
- No significant sedationpositive
- Metabolic effects
- No metabolic changespositive
- Movement disorders
- No extrapyramidal symptomspositive
- Most common
- Mild diarrhea, nauseaneutral
Typical Antipsychotic Addition
- Adverse event rate
- Typically higher than monotherapynegative
- Weight gain
- Common, dose-dependent, cumulativenegative
- Sedation
- Often significantnegative
- Metabolic effects
- Dyslipidemia, insulin resistancenegative
- Movement disorders
- Risk increases with polypharmacynegative
- Non-adherence
- >50% of patients stop due to side effectsnegative
McGuire et al. (2018), Am J Psychiatry
This is where the finding becomes transformative. In schizophrenia treatment, the side effect burden is not a footnote — it's the central problem. More than 50% of patients with schizophrenia eventually stop taking their medication, primarily because of weight gain, sedation, movement disorders, and metabolic syndrome. Non-adherence leads to relapse, hospitalization, and the devastating revolving-door pattern that defines treatment-resistant schizophrenia.
CBD produced none of these. No weight gain. No sedation. No metabolic effects. No movement disorders. The adverse event rate in the CBD group was statistically indistinguishable from placebo. Adding a molecule that improves symptoms without adding side effects is precisely what the field needs — and precisely what current pharmacology struggles to deliver.
A New Kind of Antipsychotic
Biological Mechanism
How CBD Reduces Psychotic Symptoms Without Blocking Dopamine
Current antipsychotics block D2 receptors
Every approved antipsychotic works primarily by blocking dopamine D2 receptors. This reduces hallucinations and delusions but causes movement disorders, weight gain, metabolic syndrome, and sexual dysfunction — all direct consequences of blunting dopamine signaling.
CBD doesn't touch D2 receptors
CBD has negligible affinity for dopamine D2 receptors. It does not block dopamine signaling. This is why it doesn't cause any of the classic antipsychotic side effects.
CBD raises anandamide levels
CBD inhibits FAAH, the enzyme that breaks down anandamide (the brain's own endocannabinoid). Higher anandamide levels were correlated with better clinical outcomes in Leweke's 2012 trial — the more anandamide rose, the more symptoms improved.
Additional targets
CBD also acts on 5-HT1A serotonin receptors (partial agonism), GPR55 (antagonism), and modulates neuroinflammation. These multiple targets may contribute to its antipsychotic effects through pathways completely independent of dopamine.
Result
Symptom improvement without the side effect burden that drives more than half of schizophrenia patients to stop their medication.
McGuire et al. (2018); Leweke et al. (2012)
This mechanism matters beyond the immediate finding. If CBD's antipsychotic effect operates through endocannabinoid modulation rather than dopamine blockade, it represents a genuinely new pharmacological approach to psychosis — the first since the discovery of antipsychotics in the 1950s. Seventy years of antipsychotic development have produced drugs that are better at managing side effects but all still work by the same fundamental mechanism. CBD would be the first to work differently.
The THC-CBD Paradox
McGuire's finding completes one of the most remarkable paradoxes in pharmacology. THC — one cannabinoid — increases psychosis risk, particularly at high doses and in genetically vulnerable individuals. CBD — another cannabinoid from the exact same plant — reduces psychotic symptoms in patients with established schizophrenia.
THC ↑ CBD ↓
Two molecules from the same plant with opposite effects on psychosis. THC increases risk; CBD reduces symptoms. This is why the conversation about 'cannabis and psychosis' must specify which cannabinoid.
High-THC, zero-CBD products (which dominate legal markets) carry psychiatric risk that whole-plant cannabis with both compounds may not. The ratio matters as much as the dose.
McGuire (2018), Di Forti (2019), Leweke (2012), Bhattacharyya (2010)
This has direct implications for cannabis policy and product regulation. The modern legal cannabis market has drifted toward high-THC, low-CBD products. If THC increases psychosis risk and CBD protects against it, the ratio of cannabinoids in consumer products is a public health variable — not just a consumer preference.
Limitations
The honest caveats are significant:
Industry funded. GW Pharmaceuticals (now Jazz Pharmaceuticals), the maker of Epidiolex, sponsored the trial. Several co-authors were GW employees. The pharmaceutical-grade CBD used was GW's proprietary formulation. This doesn't invalidate the results — industry-funded trials are the norm in drug development — but it means independent replication is essential.
Moderate effect size. The 1.4-point PANSS positive improvement is statistically significant but modest. This is an adjunctive effect on top of existing treatment, not a dramatic transformation. Some patients may not notice a clinically meaningful difference.
Short duration. Six weeks tells you about acute efficacy. It tells you nothing about whether the benefit persists at 6 months or 2 years, whether tolerance develops, or what the long-term safety profile looks like.
High dose, high cost. CBD at 1000 mg/day of pharmaceutical-grade product is expensive. Consumer CBD products at this dose would cost $100-300/month — prohibitive for many schizophrenia patients, who disproportionately face financial hardship.
Adjunctive only. CBD was tested as an add-on, not a replacement. Whether CBD could work as monotherapy in some patients (as Leweke's data suggested) remains untested at this scale.
Key Takeaways
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S (2018) · American Journal of Psychiatry
Can CBD cure schizophrenia?
No. This trial showed CBD can reduce positive psychotic symptoms when added to existing medication, not that it cures the condition. Schizophrenia is a chronic illness that typically requires ongoing treatment. CBD at 1000 mg/day produced a moderate improvement — meaningful for patients, but not a cure.
Should people with schizophrenia use CBD from a dispensary?
This is not recommended without medical supervision. The trial used pharmaceutical-grade CBD at a specific dose (1000 mg/day) with known purity and consistency. Consumer CBD products vary widely in quality, actual CBD content, and may contain THC — which could worsen psychotic symptoms. Any use of CBD for psychosis should be discussed with a psychiatrist.
How does this relate to cannabis causing psychosis?
THC (the psychoactive component) increases psychosis risk, especially at high doses. CBD (the non-psychoactive component) appears to reduce psychotic symptoms. These are opposite effects from different molecules in the same plant. Cannabis products high in THC and low in CBD may carry the most psychiatric risk. Products with balanced or CBD-dominant profiles may be safer — but this remains an active area of research.
Why hasn't CBD been approved as an antipsychotic?
The evidence is promising but still early. This is one 88-patient, 6-week trial. Regulatory approval requires larger trials, longer duration, and independent replication. GW Pharmaceuticals (now Jazz) has pursued further research, but as of 2026, no CBD product has been approved for schizophrenia.
What the researchers found
In 88 patients with schizophrenia already on antipsychotics, adding 1000 mg/day CBD for 6 weeks significantly reduced positive psychotic symptoms (PANSS positive difference: -1.4, p=0.019) and increased clinician-rated improvement (OR 3.65, p=0.017) versus placebo. CBD was well-tolerated with no weight gain, sedation, or metabolic effects.
Why it matters
The largest RCT of CBD for psychosis confirmed that CBD has antipsychotic properties through a mechanism completely different from all existing drugs — raising endocannabinoid levels rather than blocking dopamine. The near-zero side effect burden addresses the central problem in schizophrenia treatment: patients stop their medications because the side effects are intolerable.
The numbers in context
- 88 patients randomized (CBD 43, placebo 45)
- CBD dose: 1000 mg/day (500mg BID) for 6 weeks
- PANSS positive improvement: CBD -3.2 (SD 2.60) vs placebo -1.7 (SD 2.76)
- Treatment difference: -1.4 (95% CI: -2.5 to -0.2; p=0.019)
- CGI-I: OR 3.65 (95% CI: 1.38-9.69; p=0.017)
- Cognition (BACS): difference 1.31 (95% CI: -0.10, 2.72) — trend only
- Functioning (GAF): difference 3.0 (95% CI: -0.4, 6.4) — trend only
How the study worked
Double-blind, parallel-group, placebo-controlled, multicenter RCT. Patients with schizophrenia on stable antipsychotic medication randomized 1:1 to CBD 1000 mg/day or placebo for 6 weeks. Primary outcome: PANSS positive subscale. Secondary: PANSS total, CGI-I, CGI-S, BACS, GAF.
Who was studied
88 patients with schizophrenia (CBD: n=43, placebo: n=45), multicenter (UK, Poland, Romania), all on stable antipsychotic medication
What this study cannot tell us
Industry-funded (GW Pharmaceuticals). Moderate effect size. Short duration (6 weeks) — no long-term data. CBD tested only as adjunct, not monotherapy. High dose (1000 mg/day) is expensive. Sample size adequate for primary endpoint but underpowered for secondary outcomes.
How to read the evidence
Strong evidence: multicenter, double-blind, placebo-controlled RCT published in the top psychiatry journal. Industry-funded with moderate effect size and short duration temper the rating.
When this study was published
Published in 2018. Remains the largest published RCT of CBD for schizophrenia as of 2026. Further trials are underway.
The bigger picture
This trial completes the THC-CBD paradox: one cannabinoid increases psychosis risk, the other reduces psychotic symptoms. CBD's antipsychotic mechanism — raising endocannabinoid levels rather than blocking dopamine — represents the first truly novel pharmacological approach to psychosis since the 1950s. If confirmed in larger trials, it could change how schizophrenia is treated.
Funding
GW Pharmaceuticals (now Jazz Pharmaceuticals)
Conflicts of interest
Several co-authors (Robson, Barron, Taylor, Wright) were employees of GW Pharmaceuticals. McGuire received research funding from GW.
Questions still open
- Can CBD work as monotherapy for schizophrenia (not just adjunctive)?
- Does the benefit persist beyond 6 weeks?
- Would lower doses (e.g. 600 mg/day) be effective and more affordable?
- Can the finding be replicated independently (not industry-funded)?
Common questions
Can CBD treat schizophrenia?
How does CBD work as an antipsychotic?
Is this the same CBD sold in stores?
Read the original research
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
American Journal of Psychiatry, 175(3), 225-231
The American Journal of Psychiatry is the most prestigious journal in psychiatry, published by the American Psychiatric Association.
Citation
McGuire, Philip; Robson, Philip; Cubala, Wieslaw Jerzy; Vasile, Daniel; Morrison, Paul Dugald; Barron, Rachel; Taylor, Adam; Wright, Stephen. (2018). Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. American Journal of Psychiatry, 175(3), 225-231. https://doi.org/10.1176/appi.ajp.2017.17030325